BridgeBio Oncology Therapeutics (BBOT) financial statements
Net income was -$134M.
Free cash flow was -$114M.
The diluted share count rose 241276% over the period (dilution).
Income statement
Fiscal years, from BridgeBio Oncology Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Research and development | — | $73M | $121M |
| Selling, general and admin | $41,692 | $8M | $25M |
| Operating income | -$41,692 | -$81M | -$146M |
| Income tax | — | $0 | $0 |
| Net income | -$41,692 | -$74M | -$134M |
| EPS (diluted) | — | -$5,756.41 | -$4.30 |
| Diluted shares | — | 0M | 31M |
Balance sheet
Fiscal years, from BridgeBio Oncology Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $0 | $156M | $426M |
| Total current assets | — | $159M | $432M |
| Property, plant and equipment | — | $490,000 | $956,000 |
| Total assets | $332,894 | $164M | $448M |
| Total current liabilities | $396,463 | $20M | $35M |
| Total liabilities | $396,463 | $20M | $37M |
| Shareholders' equity | -$116M | -$179M | $411M |
| Net debt | $0 | -$31M | -$374M |
Cash flow
Fiscal years, from BridgeBio Oncology Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | — | -$55M | -$114M |
| Capital spending | — | $49,000 | $606,000 |
| Free cash flow | — | -$55M | -$114M |
| Stock-based compensation | — | $4M | $6M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BBOT.
Open BBOT in InvestinglyQuestions
How much free cash flow does BridgeBio Oncology Therapeutics generate?
-$114M in fiscal 2025 (operating cash flow minus capital spending).
From BridgeBio Oncology Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.